Research Article
[Retracted] Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
Table 2
Comparison of baseline characteristics between the two cohorts following matching.
| | H101-TACE
() | c-TACE
() | |
| | Age (years), | | | 0.989 | | Gender, (%) | | | 0.710 | | Male | 33 (91.7) | 31 (86.1) | | Female | 3 (8.3) | 5 (13.9) | | HBV, (%) | | | 1.000 | | Absent | 0 | 0 (4.1) | | Present | 36 (100) | 36 (100) | | , (%) | | | 1.000 | | 0 | 28 (77.8) | 28 (77.8) | | 1 | 8 (22.2) | 8 (22.2) | | 2 | 0 (0) | 0 (0) | | Child-Pugh, (%) | | | 0.605 | | A | 24 (66.7) | 27 (75) | | B | 12 (33.3) | 9 (25) | | BCLC, (%) | | | 1.000 | | B | 25 (69.4) | 25 (69.4) | | C | 11 (30.6) | 11 (30.6) | | Tumor number, (%) | | | 1.000 | | ≤3 | 18 (50) | 17 (47.2) | | >3 | 18 (50) | 19 (52.8) | | Tumor size (cm), (%) | | | 0.813 | | <5 | 19 (52.8) | 21 (58.3) | | ≥5 | 17 (47.2) | 15 (41.7) | | Tumor thrombus, (%) | | | 1.000 | | Absent | 34 (94.4) | 34 (94.4) | | Present | 2 (5.6) | 2 (5.6) | | Lymph node metastasis, (%) | | | 0.767 | | Absent | 28 (77.8) | 30 (83.3) | | Present | 8 (22.2) | 6 (16.7) | | Distant metastasis, (%) | | | 0.478 | | Absent | 33 (91.7) | 30 (83.3) | | Present | 3 (8.3) | 6 (16.7) | | Alpha-fetoprotein (ng/ml), (%) | | | 1.000 | | <400 | 22 (61.1) | 22 (61.1) | | ≥400 | 14 (38.9) | 14 (38.9) | | TB, | | | 0.026 | | ALB, | | | 0.899 | | ALT, | | | 0.644 | | AST, | | | 0.165 | | PT, | | | 0.421 | | Ascites, (%) | | | 0.710 | | Absent | 31 (86.1) | 33 (91.7) | | Present | 5 (13.9) | 3 (8.3) |
|
|
Abbreviations: ECOG: Eastern Cooperative Oncology Cohort; HBV: hepatitis B virus; BCLC: Barcelona clinic liver cancer; AFP: alpha-fetoprotein; TB: total bilirubin; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
|
